Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells

Carcinogenesis

Volumn 39, Issue 4, 2018, Pages 601-613

  Corominas Faja, Bruna ^a,b   Cuyàs, Elisabet ^a,b   Lozano Sánchez, Jesús ^c,d   Cufí, Sílvia ^b,n   Verdura, Sara ^a,b   Fernández Arroyo, Salvador ^e,f   Borrás Linares, Isabel ^d   Martin Castillo, Begoña ^a   Martin, Ángel G ^g   Lupu, Ruth ^h,i   Nonell Canals, Alfons ^j   Sanchez Martinez, Melchor ^j   Micol, Vicente ^k,l   Joven, Jorge ^e,f   Segura Carretero, Antonio ^c,d   Menendez, Javier A ^a,b,m  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d Research and Development of Functional Food Centre (CIDAF)   (Spain)

^e HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^f The Campus of International Excellence Southern Catalonia ^*  (Spain)

^g StemTek Therapeutics SL   (Spain)

^h MAYO CLINIC   (United States)

ⁱ MAYO CLINIC CANCER CENTER   (United States)

^j Mind the Byte SL   (Spain)

^k MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^l Instituto de Salud Carlos III   (Spain)

^m METABOSTEM   (Spain)

ⁿ Fundacio Clinic Per a la Recerca Biomedica   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; AZACITIDINE; CD24 ANTIGEN; DNA METHYLTRANSFERASE; EXTRA VIRGIN OLIVE OIL; HERMES ANTIGEN; PLANT MEDICINAL PRODUCT; RAPAMYCIN; S ADENOSYLMETHIONINE; SECOIRIDOID DECARBOXYMETHYL OLEUROPEIN AGLYCONE; UNCLASSIFIED DRUG; UVOMORULIN; ACETIC ACID; MTOR PROTEIN, HUMAN; OLEUROPEIN AGLYCONE; OLIVE OIL; PLANT EXTRACT; PYRAN DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BC CELL LINE; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER SCREENING; CANCER STEM CELL; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIOID CELL; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOPHENOTYPING; IN VITRO STUDY; MDA-MB-436 CELL LINE; MOLECULAR DYNAMICS; MOUSE; MTOR SIGNALING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCREENING TEST; SHORT TANDEM REPEAT; SUM159PT CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; PATHOLOGY;

ACETATES; ANIMALS; BREAST NEOPLASMS; DNA MODIFICATION METHYLASES; FEMALE; HUMANS; MICE; NEOPLASTIC STEM CELLS; OLIVE OIL; PLANT EXTRACTS; PYRANS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85045212469     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgy023     Document Type: Article

References (61)

1. Wicha, M.S. et al. (2006) Cancer stem cells: an old idea-a paradigm shift. Cancer Res., 66, 1883-1889.
2. Kakarala, M. et al. (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol., 26, 2813-2820.
3. Creighton, C.J. et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA, 106, 13820-13825.
4. Magee, J.A. et al. (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 21, 283-296.
5. Chaffer, C.L. et al. (2015) How does multistep tumorigenesis really proceed? Cancer Discov., 5, 22-24.
6. Menendez, J.A. (2015) The metaboloepigenetic dimension of cancer stem cells: evaluating the market potential for new metabostemnesstargeting oncology drugs. Curr. Pharm. Des., 21, 3644-3653.
7. Hu, X. et al. (2017) Cancer stem cells therapeutic target database: the first comprehensive database for therapeutic targets of cancer stem cells. Stem Cells Transl. Med., 6, 331-334.
8. Tai, M.H. et al. (2005) Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis, 26, 495-502.
9. Trosko, J.E. (2006) From adult stem cells to cancer stem cells: oct-4 gene, cell-cell communication, and hormones during tumor promotion. Ann. N. Y. Acad. Sci., 1089, 36-58.
10. Mani, S.A. et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-715.
11. Chaffer, C.L. et al. (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA, 108, 7950-7955.
12. Friedmann-Morvinski, D. et al. (2014) Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep., 15, 244-253.
13. Brooks, M.D. et al. (2015) Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell, 17, 260-271.
14. Sai, K. et al. (2000) Prevention of the down-regulation of gap junctional intercellular communication by green tea in the liver of mice fed pentachlorophenol. Carcinogenesis, 21, 1671-1676.
15. Nakamura, Y. et al. (2005) Augmentation of differentiation and gap junction function by kaempferol in partially differentiated colon cancer cells. Carcinogenesis, 26, 665-671.
16. Li, Y. et al. (2011) Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J. Nutr. Biochem., 22, 799-806.
17. Leone, A. et al. (2012) The chemopreventive role of dietary phytochemicals through gap junctional intercellular communication. Phytochem. Rev., 11, 285-307.
18. Kim, Y.S. et al. (2012) Cancer stem cells: potential target for bioactive food components. J. Nutr. Biochem., 23, 691-698.
19. Li, Y. et al. (2014) Targeting cancer stem cells by curcumin and clinical applications. Cancer Lett., 346, 197-205.
20. Li, Y. et al. (2010) Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res., 16, 2580-2590.
21. Pandey, P.R. et al. (2011) Resveratrol suppresses growth of cancer stemlike cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat., 130, 387-398.
22. Hsieh, C.Y. et al. (1999) Stem cell differentiation and reduction as a potential mechanism for chemoprevention of breast cancer. Chinese Pharm. J., 51, 15-30.
23. Mineva, N.D. et al. (2013) Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. PLoS One, 8, e73464.
24. Colomer, R. et al. (2006) Mediterranean diet, olive oil and cancer. Clin. Transl. Oncol., 8, 15-21.
25. Menendez, J.A. et al. (2006) Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9). Curr. Pharm. Biotechnol., 7, 495-502.
26. Escrich, E. et al. (2011) Olive oil, an essential component of the Mediterranean diet, and breast cancer. Public Health Nutr., 14, 2323-2332.
27. Visioli, F. et al. (2011) Extra virgin olive oil's polyphenols: biological activities. Curr. Pharm. Des., 17, 786-804.
28. Casaburi, I. et al. (2013) Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies. Mol. Nutr. Food Res., 57, 71-83.
29. Menendez, J.A. et al. (2013) Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle, 12, 555-578.
30. Obied, H.K. et al. (2008) Biosynthesis and biotransformations of phenolconjugated oleosidic secoiridoids from Olea europaea L. Nat. Prod. Rep., 25, 1167-1179.
31. Gupta, P.B. et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138, 645-659.
32. Manuel Iglesias, J. et al. (2013) Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One, 8, e77281.
33. Martin-Castillo, B. et al. (2015) Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget, 6, 32317-32338.
34. Lozano-Sánchez, J. et al. (2010) Prediction of extra virgin olive oil varieties through their phenolic profile. Potential cytotoxic activity against human breast cancer cells. J. Agric. Food Chem., 58, 9942-9955.
35. Vazquez-Martin, A. et al. (2012) Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals. Rejuvenation Res., 15, 3-21.
36. Charafe-Jauffret, E. et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res., 69, 1302-1313.
37. Korkaya, H. et al. (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene, 27, 6120-6130.
38. Duru, N. et al. (2012) HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin. Cancer Res., 18, 6634-6647.
39. Corominas-Faja, B. et al. (2014) Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget, 5, 8306-8316.
40. Tomita, H. et al. (2016) Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget, 7, 11018-11032.
41. Jung, J.W. et al. (2011) Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One, 6, e28068.
42. Smith, J.A. et al. (2010) A role for the Werner syndrome protein in epigenetic inactivation of the pluripotency factor Oct4. Aging Cell, 9, 580-591.
43. Yoshida, T. et al. (2006) Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene, 25, 6056-6066.
44. Chandhoke, A.S. et al. (2016) The ubiquitin ligase Smurf2 suppresses TGFß-induced epithelial-mesenchymal transition in a sumoylationregulated manner. Cell Death Differ., 23, 876-888.
45. Bochner, B.R. et al. (2001) Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. Genome Res., 11, 1246-1255.
46. Bourne, C.R. et al. (2012) Classifying compound mechanism of action for linking whole cell phenotypes to molecular targets. J. Mol. Recognit., 25, 216-223.
47. Mackie, A.M. et al. (2014) Biolog phenotype microarrays for phenotypic characterization of microbial cells. Methods Mol. Biol., 1096, 123-130.
48. Choi, J. et al. (2011) Sanguinarine is an allosteric activator of AMPactivated protein kinase. Biochem. Biophys. Res. Commun., 413, 259-263.
49. Kalogris, C. et al. (2014) Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. Biochem. Pharmacol., 90, 226-234.
50. Dennis, P.B. et al. (1996) The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol. Cell. Biol., 16, 6242-6251.
51. Khanfar, M.A. et al. (2015) Olive oil-derived oleocanthal as potent inhibitor of mammalian target of rapamycin: biological evaluation and molecular modeling studies. Phytother. Res., 29, 1776-1782.
52. Moffat, J.G. et al. (2014) Phenotypic screening in cancer drug discovery- past, present and future. Nat. Rev. Drug Discov., 13, 588-602.
53. Moffat, J.G. et al. (2017) Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov., 16, 531-543.
54. Liu, X. et al. (2013) Nonlinear growth kinetics of breast cancer stem cells: implications for cancer stem cell targeted therapy. Sci. Rep., 3, 2473.
55. Hsieh, A.C. et al. (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature, 485, 55-61.
56. Lamb, R. et al. (2015) Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. Oncotarget, 6, 4585-4601.
57. Pathania, R. et al. (2015) DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nat. Commun., 6, 6910.
58. Fujita, J. et al. (2008) Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell, 2, 595-601.
59. Wolter, F. et al. (2003) Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis, 24, 469-474.
60. Dogan, F. et al. (2018) Correlation between telomerase and mTOR pathway in cancer stem cells. Gene, 641, 235-239.
61. Menendez, J.A. (2015) The metaboloepigenetic dimension of cancer stem cells: evaluating the market potential for new metabostemnesstargeting oncology drugs. Curr. Pharm. Des., 21, 3644-3653.